Dataset Information

Falls in young adults: The effect of sex, physical activity, and prescription medications.

ABSTRACT: Falls are a major public health issue not only for older adults but also young adults, with fall-related injuries occurring more frequently in adult females than males. However, the sex differences in the frequency and circumstances of falls in young adults are understudied. This research quantified the frequency and circumstances of falls as a function of sex, physical activity, and prescription medications in young adults. For 16 weeks, young adult participants (N = 325; 89 males; 19.9±1.1 years) responded to a daily email asking if they had slipped, tripped, or fallen in the past 24 hours. Falls and fall-related injuries were not uncommon in young adults: 48% fell at least once, 25% fell more than once, and 10% reported an injury. The most common activities at the time of the fall for females were walking (44%) and sports (33%), and for males, sports (49%) and walking (37%). A zero-inflated Poisson model revealed that higher number of falls were associated with the following: higher levels of physical activity (p = 0.025), higher numbers of medications (p<0.0001), and being male (p = 0.008). Regarding circumstances of falling, females were more likely to be talking to a friend at the time of the fall (OR (95% CI): 0.35 (0.14-0.73); p = 0.01). For slips and trips without a fall, males and females reported the same number of slips (OR (95% CI): 0.885 (0.638-1.227) p = 0.46), but females reported more trips (OR (95% CI): 0.45 (0.30-0.67); p<0.01). Only females reported serious injuries such as concussion and fracture. In conclusion, the rate of falls in young adults was affected by physical activity levels, number of medications, and sex. Quantifying and understanding these differences leads to increased knowledge of falls across the lifespan and is instrumental in developing interventions to prevent falls.

SUBMITTER: Cho H

PROVIDER: S-EPMC8061998 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:ImportancePrescription drugs are necessary for managing complex physical and mental health conditions for more than 10 million Medicaid beneficiaries with disabilities. However, some state Medicaid programs limit the number of prescription drugs that beneficiaries can obtain monthly, which may decrease access to essential medications.ObjectiveTo examine the association between exposure to the 3-drug limit at age 21 years in Arkansas and Texas and prescription drug and health care use among beneficiaries with disabilities enrolled in Medicaid.Design setting and participantsIn this cohort study of 28 046 young adults with disabilities, difference-in-differences analysis was performed using Medicaid Analytic eXtract claims data from January 1, 2007, to December 31, 2012. Analyses were completed December 1, 2020. The analyses included Medicaid beneficiaries with disabilities in Arkansas and Texas (ie, drug cap states) or 15 comparison states without drug cap policies who became age 21 years during the study period and were continuously enrolled in fee-for-service Medicaid in the year before and after that point.ExposuresExposure to the 3-drug prescription limit at age 21 years in 2 drug cap states.Main outcomes and measuresMonthly total prescriptions and prescriptions for drugs to treat mental health conditions, total prescription drug spending, and inpatient and emergency department visits and spending in the 12 months before and after becoming age 21 years.ResultsAmong 28 046 young adults with disabilities, 8214 (29.3%) resided in drug cap states and were subject to the 3-drug limit at age 21 years. Most individuals were male (drug cap states: 61.4%, comparison states: 60.6%), and the minority were White individuals (drug cap states: 36.7%, comparison states: 49.4%). More than one-half of individuals with disabilities were diagnosed with a mental health condition before age 21 years (drug cap states: 57.0%, comparison states: 60.0%). In the year before the analyzed individuals became aged 21 years, the mean (SD) number of prescriptions per beneficiary per month was 1.58 (2.16) in drug cap states vs 1.82 (1.91) in comparison states. The drug cap policy was associated with 19.6% (95% CI, -21.3% to -17.8%; P < .001) fewer monthly prescriptions and 16.5% (95% CI, -21.9% to -10.8%; P < .001) fewer prescriptions for drugs for mental health conditions but was not associated with total prescription drug spending. The drug cap policy was associated with 13.6% (95% CI, 1.9% to 26.6%; P = .02) more inpatient admissions.Conclusions and relevanceIn this cohort study of young adults with disabilities, drug cap policies were associated with lower rates of access to important medications and higher rates of hospitalization among individuals in states with drug cap policies vs those without these policies.

Project description:ImportancePrescription medications are increasingly used among adults in the United States and many have a potential for causing depression.ObjectivesTo characterize use of prescription medications with depression as a potential adverse effect and to assess associations between their use and concurrent depression.Design, setting, and participantsFive 2-year cycles (2005-2006 through 2013-2014) of the National Health and Nutrition Examination Survey, representative cross-sectional surveys of US adults aged 18 years or older, were analyzed for use of medications with depression as a potential adverse effect. Multivariable logistic regression examined associations between use of these medications and concurrent depression. Analyses were performed among adults overall, excluding antidepressant users, and among adults treated with antidepressants and with hypertension.ExposuresPrescription medications with depression as a potential adverse effect (listed in Micromedex).Main outcomes and measuresPrevalence of any use and concurrent use of medications with a potential to cause depression and prevalence of depression (PHQ-9 score ≥10).ResultsThe study included 26 192 adults (mean age, 46.2 years [95% CI, 45.6-46.7]; women, 51.1%) and 7.6% (95% CI, 7.1%-8.2%) reported depression. The overall estimated prevalence of use of medications with depression as an adverse effect was 37.2%, increasing from 35.0% (95% CI, 32.2%-37.9%) in the cycle years 2005 and 2006 to 38.4% (95% CI, 36.5%-40.3%) in 2013 and 2014 (P for trend = .03). An estimated 6.9% (95% CI, 6.2%-7.6%) reported use of 3 or more concurrent medications with a potential for depression as an adverse effect in 2005 and 2006 and 9.5% (95% CI, 8.4%-10.7%) reported such use in 2013 and 2014 (P for trend = .001). In adjusted analyses excluding users of antidepressants, the number of medications used with depression as possible adverse effects was associated with increased prevalence of concurrent depression. The estimated prevalence of depression was 15% for those reporting use of 3 or more medications with depression as an adverse effect vs 4.7% for those not using such medications (difference, 10.7% [95% CI, 7.2%-14.1%]). These patterns persisted in analyses restricted to adults treated with antidepressants, among hypertensive adults, and after excluding users of any psychotropic medication.Conclusions and relevanceIn this cross-sectional survey study, use of prescription medications that have depression as a potential adverse effect was common. Use of multiple medications was associated with greater likelihood of concurrent depression.

Dataset Information

Falls in young adults: The effect of sex, physical activity, and prescription medications.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets